Dr. Heath on Developments in Nonmetastatic CRPC

Video

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Elisabeth I. Heath, MD, FACP, associate center director of Translational Sciences, lead of the Genitourinary Oncology Multidisciplinary Team, medical director of the Infusion Center, and director of Prostate Cancer Research at Barbara Ann Karmanos Cancer Institute, and professor of oncology at Wayne State University School of Medicine, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Nonmetastatic CRPC is defined by a rising prostate-specific antigen (PSA) in men who are on androgen deprivation therapy, says Heath. Despite this, there is no evidence of metastasis on standard imaging. The inclination for men with rising PSA, which can indicate clinical progression, is to treat. Now, providers have the option to treat with apalutamide (Erleada), enzalutamide (Xtandi), or darolutamide (Nubeqa).

All 3 agents were approved based on data that showed an improvement in metastasis-free survival (MFS), which is a newer endpoint that is now recognized by the FDA, says Heath. MFS is a new nuance in how drugs will be developed in this space, concludes Heath.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD